Innate Immune Response Affects AAV-Mediated Hepatic Trangene Expression

被引：0
|
作者：
Gil, Irene [1 ]
Di Scala, Marianna [1 ]
Vanrell, Lucia [1 ]
Vales, Africa [1 ]
Olague, Cristina [1 ]
Prieto, Jesus [1 ,2 ]
High, Kathy [3 ]
Mingozzi, Federico [3 ]
Gonzalez-Aseguinolaza, Gloria [1 ]
机构：
[1] CIMA, Pamplona, Spain
[2] Ciberehd, Pamplona, Spain
[3] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
来源：
MOLECULAR THERAPY | 2012年 / 20卷
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
258
引用
收藏
页码：S101 / S102
页数：2
相关论文
共 50 条
  • [1] Innate and adaptive AAV-mediated immune responses in a mouse model of Duchenne muscular dystrophy
    Emami, Michael R.
    Espinoza, Alejandro
    Young, Courtney S.
    Ma, Feiyang
    Farahat, Philip K.
    Felgner, Philip L.
    Chamberlain, Jeffrey S.
    Xu, Xiangmin
    Pyle, April D.
    Pellegrini, Matteo
    Villalta, S. Armando
    Spencer, Melissa J.
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2023, 30 : 90 - 102
  • [2] Causal Role for Immune Response in AAV-Mediated DRG Toxicity in NHPs
    Henry, Kate
    Bai, Judy
    Bhat, Harsha
    Burkly, Linda
    Chan, Su Jing
    Doherty, Jessica
    Glajch, Kelly
    Grubor, Branka
    Kirkland, Melissa
    Lo, Joyce
    Morris, Dale
    Pellerin, Alex
    Plowey, Ed
    Prefontaine, Annick
    Nadella, Prasad
    Sheehan, Mark
    Suh, Junghae
    Tien, Eric
    van der Munnick, Nick
    MOLECULAR THERAPY, 2023, 31 (04) : 75 - 75
  • [3] Optimization of efficacy in AAV-mediated siRNA expression
    Mzukami, H.
    Urabe, M.
    Tsukahara, T.
    Kume, A.
    Ozawa, K.
    HUMAN GENE THERAPY, 2011, 22 (10) : A104 - A105
  • [4] Response: AAV-mediated gene transfer to liver
    High, KA
    Herzog, R
    Arruda, V
    BLOOD, 2003, 101 (08) : 3338 - 3339
  • [5] Hepatic AAV-mediated gene transfer to reduce immune responses against alpha-sarcoglycan
    Poupiot, J.
    Richard, I.
    HUMAN GENE THERAPY, 2015, 26 (10) : A75 - A75
  • [6] Immune Response to AAV Vector Capsid and Assessment of Eligibility for AAV-Mediated Gene Therapy for Duchenne Muscular Dystrophy
    Saha, Rima
    Meyers, Craig
    Coleman, Kirsten
    Trivedi, Prasad
    Bhake, Radhika
    Byrne, Barry J.
    Corti, Manuela
    MOLECULAR THERAPY, 2023, 31 (04) : 546 - 547
  • [7] In contrast to AAV-mediated Cntf expression, AAV-mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal degeneration
    Buch, Prateek K.
    MacLaren, Robert E.
    Duran, Yanai
    Balaggan, Kamaljit S.
    MacNeil, Angus
    Schlichtenbrede, Frank C.
    Smith, Alexander J.
    Ali, Robin R.
    MOLECULAR THERAPY, 2006, 14 (05) : 700 - 709
  • [8] Investigating the Role of Innate Immune Signaling in AAV-Mediated Gene Transfer in hiPSC-Derived CNS Models
    Verdera, Helena Costa
    Abou Alezz, Monah
    Cavalca, Eleonora
    Meneghini, Vasco
    Mangiameli, Elisabeth
    Giordano, Maria Sole
    Singh, Inderpal
    Kuranda, Klaudia
    Ditadi, Andrea
    Merelli, Ivan
    Gritti, Angela
    Mingozzi, Federico
    Kajaste-Rudnitski, Anna
    MOLECULAR THERAPY, 2022, 30 (04) : 338 - 338
  • [9] AAV-mediated hepatic tolerance induction protects from cellular immune responses to factor IX.
    Dobrzynski, E
    Cao, O
    Wang, L
    Mingozzi, F
    Herzog, RW
    BLOOD, 2003, 102 (11) : 492A - 492A
  • [10] Innate Immune Response Following AAV Administration
    Dauletbekov, D. L.
    Pfromm, J. K.
    Fritz, A. K.
    Fischer, M. D.
    RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY, 2019, 1185 : 165 - 168
12345